Scrip    Clinica    Scrip Regulatory Affairs    Scrip Clinical Research    AnimalPharm   
Email ID
Password
Forgotten your password?
Sign me in automatically next time
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
News
|
Comment
|
Features
|
Analysis
|
Market Data
|
People
|
Events
|
Multimedia
|
Capitol Capsule
|
Stockwatch
|
FEATURED CONTENT
12 December 2015

.

 
NSCLC Drug Universe Expands: Genentech's Alecensa OK'd
11 December 2015
The universe seems to be working this year in favor of patients with non-small-cell lung cancer (NSCLC) – with a lot of help from drug makers and the FDA's ...
Will M&A Pressure Mount After Pfizer-Allergan Merger?
11 December 2015
Large biotechnology companies are poised to become major players in mergers and acquisitions due to fast-growing cash stockpiles, but the pending $160bn merger ...
ASH 2015: As CAR-T Players Vie For 1st Place, Will Efficacy Trump Safety?
11 December 2015
Data for chimeric antigen receptor T-cell (CAR-T) therapies from Novartis AG , Kite Pharma Inc. and Juno Therapeutics Inc. have shown similarly impressive ...
ASH 2015: First-In-Class Myeloma Highlights
11 December 2015
A number of first-in-class products for acute myeloid leukemia and multiple myeloma provided clinical updates during the American Society for Hematology's ...
Latin America Ploughs Ahead With Joint Pricing Strategy
11 December 2015
Pharmaceutical companies wanting to sell high-cost drugs in Latin America may find themselves talking with multiple countries at once to find a single ...
 
Post Depomed Deal Flop, Horizon Buys Crealta For $510m
12 December 2015
Horizon Pharma plc has moved on from its failed $1.7bn attempt to buy Depomed Inc. with the $510m cash purchase of Crealta Holdings LLC, which bought the developer of specialty gout drug Krystexxa ...
UnitedHealth Goes With Praluent, Snubs Repatha
12 December 2015
Regeneron Pharmaceuticals Inc. and Sanofi SA managed to get their proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitor Praluent (alirocumab) onto another big US payer's formulary – this time ...
PharmAsia News Business Bulletin
11 December 2015
A new regular roundup of commercial stories appearing in Scrip's sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on ...
Syncona Creates Second Gene Therapy Company With £25m Financing
10 December 2015
The Wellcome Trust's investment subsidiary Syncona LLP has put £25m of series A financing into a new gene therapy company, Freeline Therapeutics, spun off from University College London (UCL) via its ...
 
Puma Continues Long Post-ASCO Plunge On Latest Data
11 December 2015
Puma Biotechnology Inc.'s data for the tyrosine kinase inhibitor neratinib (PB272) in the treatment of breast cancer now seem to disappoint investors every time the Los Angeles-based company reports ...
Data Takes A Bite Out of Puma Shares
11 December 2015
Puma Biotechnology added to its portfolio of clinical data for its once-potential blockbuster neratinib at the San Antonio Breast Cancer Symposium on Dec. 10, but the positive new Phase II data still ...
Threshold Plummets As Merck Drops Evofosfamide For Sarcoma
08 December 2015
Threshold Pharmaceuticals saw its stock lose more than 80% of its value following disappointing data from two Phase III trials of its anticancer evofosfamide in advanced soft tissue sarcoma and ...
Celgene, AstraZeneca Ramp Up IO Collaboration
07 December 2015
With its PD-L1 agonist unlikely to hit the market before 2017, AstraZeneca is focusing on the drug's potential in combination therapies, announcing its latest set of clinical trials that will test ...
 
Wellstat's Chemo Overdose Antidote Vistogard Approved
12 December 2015
Privately held Wellstat Therapeutics Corp. on Dec. 11 won a speedier-than-expected FDA approval for Vistogard (uridine triacetate) as an emergency treatment to counter an overdose of 5-fluorouracil ...
Russia Turns The Screw On Foreign-Made Drugs
11 December 2015
Pharmaceutical firms operating in Russia and some of its neighbouring countries might want to cast an eye over their local manufacturing strategy after the government imposed new restrictions on ...
Keytruda, Ibrance On Course To India Debut But What About Pricing?
08 December 2015
Merck & Co's Keytruda (pembrolizumab), the first PD-1 inhibitor approved by the FDA last year, and Pfizer's breast cancer therapy, Ibrance (palbociclib), appear to be on course to a potential Indian ...
Alexion's Rare Bone Drug Strensiq 'Not Value For Money'
03 December 2015
NICE, the HTA body for England and Wales, has issued draft guidance that does not recommend Alexion's rare bone disease treatment Strensiq (asfotase alfa) for pediatric-onset hypophosphatasia. ...
 
RECENT TWEETS    
12 December 2015





US CAPITOL CAPSULE


Time To Get Aggressive Against Trade Secret Bandits

Also covered:

• Senators Fear Viral Spread Of Gilead Pricing Strategy
• Jimmy Carter Credits Merck's Keytruda For Cancer-Free Success
• Greed Kicking The Savings Out Of Generic Drugs?
• Express Scripts Turns To Tailor-Made To Tackle Turing
• Plus other Washington news


Read more...

 
Engaging The Tech Savvy Physician: Mind The Gaps
02 December 2015
Anju Ghangurde

Can Pharma Sustain Earnings As Tax Oversight Tightens?
09 December 2015



MULTIMEDIA
Outlook of Big Pharma - Part 1 17 July 2015

Get the Flash Player to see this player.

Technology Dreams Of Its Pharma Future
08 December 2015
Data Integrity Inspections Go Global
08 December 2015
A Day Of Reckoning for Aging Facilities: Is It Time To Invest In Change?
08 December 2015

The secrets behind GSK's strategic sauce
02 December 2015
Lisa LaMotta

EXCLUSIVE EMA 20th anniversary supplement
18 March 2015

Celebrations at the 11th Annual Scrip Awards
02 December 2015

PEOPLE
Alzheon Appoints Chair
Avacta Appoints CFO
>> More People News...

EVENTS
11 January 2016
Parc 55, San Francisco, CA USA
20 January 2016
PGA National, Palm Beach Gardens, FL
JOB OF THE WEEK Promote your job vacancy
© 2015 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Terms & Conditions
Privacy Policy
Sitemap
About Us
Advertise
Subscribe
Scrip
Clinica
Scrip Regulatory Affairs
Scrip Clinical Research
Animal Pharm